Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

RBOT.WS vs ZBH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZBH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

ZBH Overall Winner 6-Pillar Tally: RBOT.WS 0 – 6 ZBH Matrix Metrics: RBOT.WS 1 – 9 ZBH

As of Nov 20, 2026, Zimmer Biomet Holdings, Inc. (ZBH) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ZBH carries 46.6/100 (HOLD) at $101.10 (11.3x Forward P/E, 16.7% operating margin).

  • Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ZBH 46.6/100 HOLD), ZBH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.7% vs. N/A operating margin) and revenue trajectory (+3.1% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RBOT.WS vs ZBH
RBOT.WS NYSE
Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$0.01
-24.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol N/A
Unified Composite Score
50.1 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ZBH NYSE Head-to-Head Winner
Zimmer Biomet Holdings, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$101.10
-0.36% 1D
Market Cap $19.2B
TTM Revenue $8.57B
Forward P/E 11.3x
Beta / 30D Vol 0.40β · 54% Vol
Unified Composite Score
46.6 / 100 HOLD
Tech 36.0 Fund 48.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 51
RSI-14: 51.0 · SMA20: $101.96 · SMA50: $96.50

6-Pillar Scorecard Institutional Category Breakdown (RBOT.WS 0 – 6 ZBH)

Columns: Metric · RBOT.WS · ZBH
1. Valuation Multiples ZBH
Forward P/E N/M 11.3x
Trailing P/E N/M 25.6x
PEG Ratio N/M 2.17x
EV / Revenue N/M 3.1x
2. Growth & Scale ZBH
Revenue Growth (YoY) N/A +3.1%
Earnings Growth (YoY) N/A -13.8%
TTM Revenue (USD) N/A $8.57B
Market Cap N/A $19.2B
3. Profitability & Quality ZBH
Gross Margin N/A 69.3%
Operating Margin N/A 16.7%
Net Profit Margin N/A 8.9%
Return on Equity (ROE) N/A 6.0%
4. Balance Sheet & Cash Flow ZBH
Cash Generation (TTM) N/A $1.51B
Cash Flow Margin N/A 17.6%
Net Cash / Leverage N/A ROE $7.10B Net Debt (0.59x D/E)
Dividend Yield None (0.00%) 0.93%
5. Options & Positioning ZBH
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 133.3% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat ZBH
OpEx & R&D Intensity N/A 52.6% of Rev ($4.51B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RBOT.WS (1) vs ZBH (9)
Institutional Metric RBOT.WS ZBH Criterion Row Edge
Market Capitalization
Scale
N/A $19.2B Larger Scale ZBH
Trailing P/E Ratio
Valuation
N/M 25.6x Lower Multiple ZBH
Forward P/E Ratio
Valuation
N/M 11.3x Lower Multiple ZBH
Revenue Growth (YoY)
Growth
N/A +3.1% Higher Growth ZBH
Operating Margin (TTM)
Profitability
N/A 16.7% Higher Margin ZBH
Net Profit Margin
Profitability
N/A 8.9% Higher Margin ZBH
Return on Equity (ROE)
Capital Efficiency
N/A 6.0% Higher ROE ZBH
52-Week Range Position
Momentum
0% ($0–$0) 66% ($79–$113) Stronger Trend ZBH
Beta / 30D Volatility
Risk Regime
N/A 0.40β · 54% Vol Lower Realized Risk ZBH
Unified Institutional Score
Composite Signal
50.1 / 100 (HOLD) 46.6 / 100 (HOLD) Higher Composite RBOT.WS
Trailing 12M Revenue (USD)
Operating Scale
N/A $8.57B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 69.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.17x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $1.51B ($7.10B Net Debt (0.59x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBH +70.93 pp
RBOT.WS: -67.2% · ZBH: +3.73%
3M Horizon ZBH +70.93 pp
RBOT.WS: -67.2% · ZBH: +3.73%
6M Horizon ZBH +70.93 pp
RBOT.WS: -67.2% · ZBH: +3.73%
1Y Horizon ZBH +70.93 pp
RBOT.WS: -67.2% · ZBH: +3.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RBOT.WS vs ZBH. Trailing 12-month operating profitability (RBOT.WS N/A vs ZBH 16.7%) and valuation multiples (RBOT.WS N/M vs ZBH 11.3x Forward P/E) are benchmarked directly in Pillar 4 below.

RBOT.WS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ZBH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$8.57B
Gross Margin69.3%
Op. Margin16.7%
ROE / Fwd P/E6.0% · 11.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RBOT.WS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RBOT.WS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 133.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ZBH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $101.41 · IV 34.7%

ZBH Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($10,141)

Compare $10,141 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 34.7% ATM IV.

PUT-WALL MONTHLY INCOME Liq C

Dec 18 $95 / $90 Bull Put Spread

Sell 1x $95P · Buy 1x $90P · 31d

Net Entry $69 Credit
Max Credit / Yield +$69 (+16.0% RoM)
Max Risk / Buffer -7.0% Cushion ($431 Mgn)
5d Edge & Liquidity 79% PoP · Liq C
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq C

Dec 18 $100 / $95 Bear Put Spread

Buy 1x $100P · Sell 1x $95P · 31d

Net Entry $170 Debit
T+5d @ -5% Drop +$108 (+63%)
Max Risk / Buffer $170 Capped
5d Edge & Liquidity 1.0x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RBOT.WS Moat Profile Cyclical / Execution-Driven Positioning
Orthopedic, Prosthetic & Surgical Appliances & Supplies Operator
Competes within the Orthopedic, Prosthetic & Surgical Appliances & Supplies value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZBH Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $19.2B market capitalization and 16.7% operating margin.
OpEx & R&D Reinvestment 52.6% of Rev ($4.51B)
90D Engineering Disclosures 0 Published

Investor FAQ RBOT.WS vs ZBH Key Questions & Quantitative Answers

As of Nov 20, 2026, Zimmer Biomet Holdings, Inc. (ZBH) is the stronger overall head-to-head candidate over Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of (RBOT.WS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RBOT.WS carries a Unified Composite Score of 50.1/100 (HOLD) at $0.01 (N/M Forward P/E, N/A operating margin), whereas ZBH carries 46.6/100 (HOLD) at $101.10 (11.3x Forward P/E, 16.7% operating margin). Composite vs. Pillar Nuance: While RBOT.WS currently prints a higher short-term Unified Composite Score (50.1/100 HOLD vs. ZBH 46.6/100 HOLD), ZBH captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (16.7% vs. N/A operating margin) and revenue trajectory (+3.1% vs. N/A YoY).

ZBH leads the Growth & Scale pillar: RBOT.WS posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ZBH at +3.1% YoY revenue growth and -13.8% YoY earnings growth on $8.57B TTM revenue (69.3% gross margin, 16.7% operating margin). On trailing 12-month operating scale, RBOT.WS generates N/A in USD-normalized revenue versus $8.57B for ZBH. In operating R&D and SG&A reinvestment, RBOT.WS deploys N/A (0 90-day corporate R&D disclosures) versus 52.6% of Rev ($4.51B) (0 disclosures) for ZBH.

ZBH screens cheaper on headline valuation multiples. RBOT.WS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ZBH trades at 11.3x Forward P/E, 25.6x Trailing P/E, 2.17x PEG, and 3.1x EV/Revenue (17.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RBOT.WS (N/A ROE) versus ZBH (6.0% ROE) capital efficiency.

In options market volatility and institutional positioning, RBOT.WS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (N/A realized risk). By comparison, ZBH carries 133.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.40β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Vicarious Surgical Inc. Warrants, each whole warrant exercisable for 1/30th of a share of Class A Common Stock at an exercise price of $345.00 (RBOT.WS) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.